- Home
- WEX vs LEGN Comparison
WEX vs LEGN Comparison
Compare WEX & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WEX
- LEGN
- Stock Information
- Founded
- WEX 1983
- LEGN 2014
- Country
- WEX United States
- LEGN United States
- Employees
- WEX N/A
- LEGN N/A
- Industry
- WEX Business Services
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- WEX Consumer Discretionary
- LEGN Health Care
- Exchange
- WEX Nasdaq
- LEGN Nasdaq
- Market Cap
- WEX 5.8B
- LEGN 6.3B
- IPO Year
- WEX 2005
- LEGN 2020
- Fundamental
- Price
- WEX $159.57
- LEGN $32.02
- Analyst Decision
- WEX Hold
- LEGN Strong Buy
- Analyst Count
- WEX 13
- LEGN 12
- Target Price
- WEX $173.91
- LEGN $70.82
- AVG Volume (30 Days)
- WEX 282.2K
- LEGN 1.5M
- Earning Date
- WEX 10-29-2025
- LEGN 11-11-2025
- Dividend Yield
- WEX N/A
- LEGN N/A
- EPS Growth
- WEX 37.64
- LEGN N/A
- EPS
- WEX 7.93
- LEGN N/A
- Revenue
- WEX $2,598,200,000.00
- LEGN $796,838,000.00
- Revenue This Year
- WEX $1.13
- LEGN $70.27
- Revenue Next Year
- WEX $5.42
- LEGN $50.28
- P/E Ratio
- WEX $20.15
- LEGN N/A
- Revenue Growth
- WEX N/A
- LEGN 74.75
- 52 Week Low
- WEX $110.45
- LEGN $27.34
- 52 Week High
- WEX $191.43
- LEGN $47.79
- Technical
- Relative Strength Index (RSI)
- WEX 53.14
- LEGN 43.58
- Support Level
- WEX $146.74
- LEGN $31.60
- Resistance Level
- WEX $153.88
- LEGN $33.09
- Average True Range (ATR)
- WEX 4.38
- LEGN 1.48
- MACD
- WEX 1.15
- LEGN 0.08
- Stochastic Oscillator
- WEX 81.43
- LEGN 31.02
About WEX WEX Inc. common stock
WEX Inc is a provider of corporate payment solutions. The company operates three business segments: Mobility, Benefits, and Corporate Payments. Mobility segment, the top segment by revenue, provides fleet vehicle payment solutions, transaction processing, and information management services for commercial and government fleets. The Corporate Payments segment offers business-to-business payment processing and transaction monitoring services. The Benefits segment generates revenue from healthcare payment products and its consumer-directed software platform. The company's prime end market is the United States of America.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.